{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreihcslfk7uabt224ygdryqi6aosa54t5mdizjaxibi3khvqyl7kw6i",
    "uri": "at://did:plc:2gbt2dlwaqovtnmxkat3tyke/app.bsky.feed.post/3mk2sex3gzqd2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreiatdcdox7urb7pxombf34qwwhqeemx22mzwu74opp525pt2jmte2y"
    },
    "mimeType": "image/jpeg",
    "size": 240403
  },
  "path": "/articles/d41586-026-01243-y",
  "publishedAt": "2026-04-22T05:48:46.252Z",
  "site": "https://www.nature.com",
  "tags": [
    "doi:10.1038/d41586-026-01243-y"
  ],
  "textContent": "Nature, Published online: 21 April 2026; doi:10.1038/d41586-026-01243-y\n\nA fresh approach to trialling treatments for rare genetic diseases could make their production an economically viable prospect at last.",
  "title": "Personalized CRISPR therapies could soon reach thousands — here’s how",
  "updatedAt": "2026-04-21T00:00:00.000Z"
}